Strand Life Sciences Introduces Scientific Advisory Board

AURORA, Colo., May 13, 2015 /PRNewswire/ -- Strand Life Sciences, a global genomic profiling company that uses next-generation sequencing technology to empower cancer care, today announced the appointment of its scientific advisory board.

"Our scientific advisory board members are thought-leaders in genetics and molecular biology who will help guide the work of the more than 200 scientists and engineers we employ to advance our pan-cancer genomic profiling technology," said Scott A. Storrer, global president of Strand Life Sciences. "The board's expertise will be invaluable as we continue to enhance StrandAdvantage to enable more personalized care for patients with cancer."

Available now to physicians, StrandAdvantage was designed to accelerate the analysis of therapeutically actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests. StrandAdvantage provides oncologists with clinically actionable results beginning with a report on eight "standard-of-care" genes delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.

The board member appointments are:

Dr. Adam Bass, an assistant professor of medicine at the Harvard School of Medicine and an Associate Member of the Broad Institute. Dr. Bass also is a physician/scientist at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. He earned his M.D. from the Duke University School of Medicine, completed a residency in internal medicine at the Massachusetts General Hospital and a fellowship in medical oncology at the Dana-Farber/Partners Cancer Center followed by training in cancer genomics at the Broad Institute and Dana-Farber. 

Dr. Charles Cantor, founder and chief scientific officer of Sequenom Inc. Dr. Cantor previously served as chair of the Department of Biomedical Engineering and Biophysics and as director of the Center for Advanced Biotechnology at Boston University. He also held positions in chemistry, genetics and development at Columbia University, and in molecular biology at the University of California, Berkeley, and served as director of the Department of Energy's Human Genome Center project at the Lawrence Berkeley Laboratory. He earned his doctorate from the University of California, Berkeley. Dr. Cantor completed the first textbook on Genomics, entitled "The Science and Technology of the Human Genome Project."

Dr. Jeffrey Kern, chief of the Division of Oncology at National Jewish Health and professor of medicine at the University of Colorado at Denver Health Sciences Center. Dr. Kern previously served as the chief of pulmonary, critical care and sleep medicine at Case Western University. He earned his M.D. from the University of Wisconsin School of Medicine, completed a residency in internal medicine at Parkland Memorial Hospital and a fellowship in pulmonary medicine and critical care at the Hospital of the University of Pennsylvania.

Dr. Herbert Kim Lyerly, professor of surgery, assistant professor in immunology and associate professor of pathology at the Duke University School of Medicine. Dr. Lyerly received his M.D. from the University of California, Los Angeles, David Geffen School of Medicine, and completed a residency in surgery and a fellowship in research at the Duke University Medical Center.

About Strand Life Sciences  
Strand Life Sciences is a genomic profiling company that uses next-generation sequencing (NGS) technology aimed at empowering cancer care. Strand's StrandAdvantage pan-cancer panels provide oncologists and pathologists a complete understanding of genomic changes in solid tumors in days so targeted treatment plans can begin quickly. Strand's comprehensive knowledge base of genomic variants linked to FDA-approved targeted cancer therapies and drugs in open clinical trials provides clinically actionable treatment options, enabling clinicians to develop a truly personalized treatment regimen for cancer patients.

For more information, please visit www.strandls.com.

Contact:

Doreen Korba
Vice President, Global Marketing
888-801-9164
[email protected]

David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
(212) 845-4271
(212) 845-4235
[email protected]  
[email protected]

SOURCE Strand Life Sciences

Related Links

http://www.strandls.com